Literature DB >> 19107335

The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study.

Michio Hongo1, Yoshikazu Kinoshita, Hiroto Miwa, Kiyoshi Ashida.   

Abstract

BACKGROUND: Patients with reflux esophagitis (RE) in Western countries have impaired health-related quality of life (HRQOL). However, few data are available concerning HRQOL in Asian patients with RE. AIM: To determine the demographic characteristics, HRQOL, and the impact of lansoprazole treatment in a large cohort of RE patients in Japan.
METHODS: Patients with RE were enrolled. Lansoprazole was administered for 8 weeks and HRQOL assessed using the SF-8 and a newly developed questionnaire for RE-specific HRQOL (RESQ) at baseline and after 4 and 8 weeks of treatment.
RESULTS: Among enrolled patients, 2320 patients with the Los Angeles classification grade A to D esophagitis at enrollment to the study were analyzed. A higher proportion of older women was observed (in the group of patients aged >or=60 years, 61.3% were women). Prevalence of obesity was 4.7%. At baseline, HRQOL scores of RE patients were well below the mean for the Japanese general population in all domains of the SF-8. After 8 weeks of treatment with lansoprazole, these scores significantly improved to the levels of the general population (P < 0.01). Scores of RESQ also significantly improved (P < 0.01).
CONCLUSIONS: Demographically, RE patients in Japan differ from those in Western countries with an increased proportion in older women and lower prevalence of obesity. RE has a marked negative impact on HRQOL, which is significantly improved by treatment with lansoprazole.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19107335     DOI: 10.1007/s00535-008-2257-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  24 in total

1.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China.

Authors:  Minhu Chen; Lishou Xiong; Huixin Chen; Angao Xu; Longjun He; Pinjin Hu
Journal:  Scand J Gastroenterol       Date:  2005-07       Impact factor: 2.423

Review 3.  Time trends of gastroesophageal reflux disease: a systematic review.

Authors:  Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-04       Impact factor: 11.382

4.  A prospective study of the prevalence of gastroesophageal reflux disease and confounding factors.

Authors:  Takenori Shimazu; Toshiyuki Matsui; Keiichi Furukawa; Kaname Oshige; Tomoko Mitsuyasu; Akihiko Kiyomizu; Toshiharu Ueki; Tsuneyoshi Yao
Journal:  J Gastroenterol       Date:  2005-09       Impact factor: 7.527

Review 5.  Minimal changes in reflux esophagitis: red ones and white ones.

Authors:  Michio Hongo
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

6.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

7.  [Quality of life in patients with Japanese cedar pollinosis: using the SF-8 health status questionnaire (Japanese version)].

Authors:  Tsukasa Fujii; Satoshi Ogino; Hiroe Arimoto; Morihiro Irifune; Nobuko Iwata; Ichiro Ookawachi; Hiroshi Kikumori; Ritsu Seo; Mariko Takeda; Akiko Tamaki; Kenji Baba; Michihiro Nose
Journal:  Arerugi       Date:  2006-10

8.  Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.

Authors:  M Feldman; W V Harford; R S Fisher; R E Sampliner; S B Murray; P A Greski-Rose; D E Jennings
Journal:  Am J Gastroenterol       Date:  1993-08       Impact factor: 10.864

9.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

Review 10.  Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire?

Authors:  V Stanghellini; D Armstrong; H Mönnikes; K D Bardhan
Journal:  Aliment Pharmacol Ther       Date:  2004-03-01       Impact factor: 8.171

View more
  11 in total

1.  Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.

Authors:  Yoshikazu Kinoshita; Hiroto Miwa; Katsuyuki Sanada; Koji Miyata; Ken Haruma
Journal:  J Gastroenterol       Date:  2013-05-08       Impact factor: 7.527

2.  Feasibility, reliability, and validity of the Japanese version of the 12-item World Health Organization Disability Assessment Schedule-2 in preoperative patients.

Authors:  Mitsuru Ida; Yusuke Naito; Yuu Tanaka; Yasunori Matsunari; Satoki Inoue; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2017-04-04       Impact factor: 2.078

3.  Dissociation and dispersion of claudin-3 from the tight junction could be one of the most sensitive indicators of reflux esophagitis in a rat model of the disease.

Authors:  Masako Oguro; Masato Koike; Takashi Ueno; Daisuke Asaoka; Hiroki Mori; Akihito Nagahara; Yasuo Uchiyama; Sumio Watanabe
Journal:  J Gastroenterol       Date:  2011-03-05       Impact factor: 7.527

4.  Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan.

Authors:  Michio Hongo; Hiroto Miwa; Motoyasu Kusano
Journal:  J Gastroenterol       Date:  2010-11-17       Impact factor: 7.527

5.  Gastro-esophageal reflux disease: the recent trend in Japan.

Authors:  Hiroto Miwa; Tadayuki Oshima; Toshihiko Tomita; Yongmin Kim; Kazutoshi Hori; Takayuki Matsumoto
Journal:  Clin J Gastroenterol       Date:  2008-12-02

6.  A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life.

Authors:  Akira Mizuki; Masayuki Tatemichi; Terue Sakakibara; Yukihiko Miura; Shigeyuki Zeki; Mitsuru Ohata; Kenji Matsuo; Fumio Kawamura; Hiroshi Nagata
Journal:  Curr Ther Res Clin Exp       Date:  2016-11-25

7.  Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study.

Authors:  Yoshikazu Kinoshita; Michio Hongo; Motoyasu Kusano; Yoshinori Furuhata; Hideaki Miyagishi; Satoshi Ikeuchi
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

8.  Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.

Authors:  Kouichi Sakurai; Hiroko Suda; Satomi Fujie; Takayuki Takeichi; Ayako Okuda; Tetsuya Murao; Kiwamu Hasuda; Masahiro Hirano; Kiyoharu Ito; Katsuie Tsuruta; Masahiro Hattori
Journal:  Dig Dis Sci       Date:  2018-11-10       Impact factor: 3.199

9.  Double Tract Reconstruction Reduces Reflux Esophagitis and Improves Quality of Life after Radical Proximal Gastrectomy for Patients with Upper Gastric or Esophagogastric Adenocarcinoma.

Authors:  Xin Ji; Chenggen Jin; Ke Ji; Ji Zhang; Xiaojiang Wu; Ziyu Jia; Zhaode Bu; Jiafu Ji
Journal:  Cancer Res Treat       Date:  2020-12-29       Impact factor: 4.679

10.  Linked color imaging improves visibility of reflux esophagitis.

Authors:  Tsutomu Takeda; Daisuke Asaoka; Daiki Abe; Maiko Suzuki; Yuta Nakagawa; Hitoshi Sasaki; Yoshihiro Inami; Muneo Ikemura; Hisanori Utsunomiya; Shotaro Oki; Nobuyuki Suzuki; Atsushi Ikeda; Noboru Yatagai; Hiroyuki Komori; Yoichi Akazawa; Kohei Matsumoto; Kumiko Ueda; Hiroya Ueyama; Yuji Shimada; Kenshi Matsumoto; Mariko Hojo; Taro Osada; Shuko Nojiri; Akihito Nagahara
Journal:  BMC Gastroenterol       Date:  2020-10-27       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.